Antiangiogenic Agents in Combination with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer

Most patients with non-small cell lung cancer (NSCLC) present with advanced disease requiring systemic chemotherapy. Treatment with the antiangiogenic agent bevacizumab in combination with standard platinum-based doublet chemotherapy has been shown to improve outcomes in patients with advanced NSCLC...

Descripción completa

Detalles Bibliográficos
Autores principales: Ulahannan, Susanna V, Brahmer, Julie R
Formato: Texto
Lenguaje:English
Publicado: Informa Healthcare 2011
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3082199/
https://www.ncbi.nlm.nih.gov/pubmed/21469981
http://dx.doi.org/10.3109/07357907.2011.554476
_version_ 1782202276199268352
author Ulahannan, Susanna V
Brahmer, Julie R
author_facet Ulahannan, Susanna V
Brahmer, Julie R
author_sort Ulahannan, Susanna V
collection PubMed
description Most patients with non-small cell lung cancer (NSCLC) present with advanced disease requiring systemic chemotherapy. Treatment with the antiangiogenic agent bevacizumab in combination with standard platinum-based doublet chemotherapy has been shown to improve outcomes in patients with advanced NSCLC. Several multitargeted antiangiogenic tyrosine kinase inhibitors (e.g., sorafenib, sunitinib, cediranib, vandetanib, BIBF 1120, pazopanib, and axitinib) are also being evaluated in combination with standard chemotherapy. Here we review current clinical data with combination therapy involving antiangiogenic agents and cytotoxic chemotherapy in patients with advanced NSCLC.
format Text
id pubmed-3082199
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Informa Healthcare
record_format MEDLINE/PubMed
spelling pubmed-30821992011-04-27 Antiangiogenic Agents in Combination with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer Ulahannan, Susanna V Brahmer, Julie R Cancer Invest Review Most patients with non-small cell lung cancer (NSCLC) present with advanced disease requiring systemic chemotherapy. Treatment with the antiangiogenic agent bevacizumab in combination with standard platinum-based doublet chemotherapy has been shown to improve outcomes in patients with advanced NSCLC. Several multitargeted antiangiogenic tyrosine kinase inhibitors (e.g., sorafenib, sunitinib, cediranib, vandetanib, BIBF 1120, pazopanib, and axitinib) are also being evaluated in combination with standard chemotherapy. Here we review current clinical data with combination therapy involving antiangiogenic agents and cytotoxic chemotherapy in patients with advanced NSCLC. Informa Healthcare 2011-05 2011-04-06 /pmc/articles/PMC3082199/ /pubmed/21469981 http://dx.doi.org/10.3109/07357907.2011.554476 Text en © 2011 Informa Healthcare http://creativecommons.org/licenses/by/2.0/ This is an open access article distributed under the Supplemental Terms and Conditions for iOpenAccess articles published in Informa Healthcare journals (http://www.informaworld.com/mpp/uploads/iopenaccess_tcs.pdf) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Ulahannan, Susanna V
Brahmer, Julie R
Antiangiogenic Agents in Combination with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer
title Antiangiogenic Agents in Combination with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer
title_full Antiangiogenic Agents in Combination with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer
title_fullStr Antiangiogenic Agents in Combination with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer
title_full_unstemmed Antiangiogenic Agents in Combination with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer
title_short Antiangiogenic Agents in Combination with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer
title_sort antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3082199/
https://www.ncbi.nlm.nih.gov/pubmed/21469981
http://dx.doi.org/10.3109/07357907.2011.554476
work_keys_str_mv AT ulahannansusannav antiangiogenicagentsincombinationwithchemotherapyinpatientswithadvancednonsmallcelllungcancer
AT brahmerjulier antiangiogenicagentsincombinationwithchemotherapyinpatientswithadvancednonsmallcelllungcancer

Ejemplares similares